Korro Bio, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Korro Bio, Inc. now
Current reporting with the operating signal separated from the noise.
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Investors are testing whether Korro Bio, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Korro Bio, Inc. Reports Progress in KRRO-110 Clinical Study for Alpha-1 Antitrypsin Deficiency and Financial Results for 2024
The story matters when it changes Korro Bio, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest KRRO filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Korro Bio, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →